Third Place winner of the RESI San Diego Innovator’s Pitch Challenge, FELIQS is developing innovative therapies for neonatal ophthalmology and other serious retinal diseases with the goal of preserving vision at the earliest stages of life. In this interview, Kenichiro “Nobu” Kuninobu discusses the company’s lead clinical program, the value of participating in the RESI Innovator’s Pitch Challenge, and the milestones that will shape FELIQS’ next phase of growth.

Kenichiro “Nobu” Kuninobu Co-founder & CEO, FELIQS

Caitlin Dolegowski Program Director, LSN

Caitlin Dolegowski (CD): FELIQS is focused on developing therapies for neonatal ophthalmology and other serious retinal diseases. Can you tell us about your lead program and the impact it could have on patients and their families?

Kenichiro Kuninobu (NK): FELIQS’ lead program, FLQ-101, is being developed for the prevention of retinopathy of prematurity, or ROP, a serious retinal disease affecting premature infants that can lead to lifelong visual impairment or blindness. Today, treatment is generally initiated after ROP has already progressed to a clinically significant stage. Our goal with FLQ-101 is to intervene earlier and prevent disease progression before invasive treatment becomes necessary. If successful, this approach could give premature infants the best possible opportunity for healthy visual development. For families, the impact could be profound. Preserving vision at the very beginning of life can influence a child’s development, independence, and quality of life, while potentially reducing a lifelong burden of care for families and healthcare systems.

CD: Your work bridges scientific innovation and international collaboration. How has that global perspective influenced the company’s development?

NK: FELIQS was founded on scientific discoveries originating in Japan, but from the beginning we have approached drug development with a global perspective. Our lead clinical program is being developed in the United States, while we continue to work closely with researchers, clinicians, regulators, and partners across Japan and other regions. That international approach has shaped how we think about clinical development, regulatory strategy, patient access, and partnerships. It also allows us to bring together complementary expertise from different regions. For diseases such as ROP, which affect premature infants around the world, we believe that building a globally relevant development strategy from an early stage is particularly important.

CD: Earning Third Place in the RESI San Diego Innovator’s Pitch Challenge highlights the strength of your innovation. What did this recognition mean to your team?

NK: Earning Third Place at the RESI San Diego Innovator’s Pitch Challenge was very meaningful to the FELIQS team. It provided encouraging external recognition of both our scientific approach and our mission to address serious retinal diseases in vulnerable patient populations, particularly premature infants. For our team, it was especially valuable to see investors and industry experts respond positively to our strategy and the potential of our programs. The recognition gave us additional confidence that FELIQS is pursuing an important and differentiated approach, while also increasing our visibility within the global life sciences community.

CD: Were there any conversations with investors, judges, or strategic partners at RESI that stood out or created new opportunities?

NK: RESI created a valuable forum for high-quality conversations with investors, judges, and potential strategic partners who understood both the unmet need in retinal disease and the importance of early intervention in ROP. Several discussions helped us refine our communication of the clinical and commercial opportunity, and some opened the door to follow-up conversations about financing, development strategy, and potential collaboration. The event was particularly useful because the feedback was practical, thoughtful, and directly relevant to our next stage of growth.

CD: What are the most important clinical, regulatory, or business milestones FELIQS hopes to achieve over the next 12 to 18 months?

NK: Over the next 12 to 18 months, our highest priority is to advance FLQ-101 clinically and build the foundation for its next stage of development. This includes progressing our ongoing clinical study in ROP, expanding our clinical network, generating additional data, and continuing regulatory discussions to define an efficient path forward.

At the same time, we plan to advance our broader pipeline, including FLQ-103 and FLQ-105, while continuing to strengthen the company financially and strategically.

From a business perspective, we are actively engaging with investors and potential strategic partners who can help us accelerate these programs. Ultimately, each of these milestones is focused on one objective: moving promising science into meaningful therapies for patients as efficiently and rigorously as possible.

CD: What qualities are you looking for in investors or strategic partners as you continue to grow?

NK: We are looking for investors and strategic partners who share our commitment to developing meaningful therapies for serious retinal diseases and who understand that building innovative medicines requires both scientific rigor and long-term perspective.

Beyond financial support, we particularly value partners who can contribute strategic insight, experience in ophthalmology, rare diseases, or global drug development, and access to networks that can help accelerate clinical and commercial progress.

Most importantly, we want partners who are collaborative and aligned with our mission. We believe the strongest partnerships are built when both sides share a long-term commitment to creating meaningful value for patients.

CD: Looking ahead, what is your long-term vision for FELIQS, and what advice would you offer companies considering participating in a future RESI Innovator’s Pitch Challenge?

NK: Our long-term vision is to establish FELIQS as a leading biotechnology company in neonatal ophthalmology and rare diseases. Building from our work in ROP, we aim to expand into additional diseases where early and innovative therapeutic intervention could preserve vision and meaningfully change patients’ lives.

For companies considering participating in a future RESI Innovator’s Pitch Challenge, my advice would be to come with a clear story, a focused objective, and an openness to feedback. RESI is not simply an opportunity to pitch your company. It is a platform to refine your strategy, understand how investors perceive your opportunity, and build relationships that may continue well beyond the event.

Additional Innovator’s Pitch Challenge (IPC) slots are now available, giving companies the opportunity to pitch directly to investors, receive live feedback, and boost visibility ahead of the event. Applications close August 26.